Martin Pule is a Clinical Senior Lecturer in the department of Haematology at University College London’s Cancer Institute and also serves as an Honorary Consultant in Haematology at University College London Hospital. His research is focused on many aspects of genetic engineering of T-cells for cancer treatment, with a particular focus on CARs. He is the founder of a UK-based biotech, Autolus, which is working on developing novel CAR-T therapies for patients with blood cancers. He holds a Bachelor of Medicine and Bachelor of Surgery from University College Dublin and is a Fellow of the Royal College of Pathologists.